Leuprolide vs MGF (Mechano Growth Factor)
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
LeuprolideAnabolic & IGF
MGF (Mechano Growth Factor)- Summary
- Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
- MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
- Half-Life
- ~3 hours (SC/IM), but depot formulations last 1–12 months
- Native MGF: minutes. PEG-MGF: ~3 days
- Admin Route
- SubQ, IM
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
- 200–400 mcg
- Frequency
- Per depot schedule
- 1–2 times per week
- Key Benefits
- Medical: reduces testosterone in prostate cancer
- Medical: suppresses estrogen in endometriosis and uterine fibroids
- Medical: delays precocious puberty
- Research: testosterone rebound effect after short course
- Transgender care: hormone suppression in adolescents
- Research: hormonal re-sensitization protocols
- Activates muscle satellite cells for repair and growth
- Accelerates recovery from muscle damage
- Synergistic with IGF-1 LR3 (different mechanisms)
- Promotes muscle hypertrophy specifically at exercised muscles
- Faster recovery between training sessions
- Potential for injury repair in connective tissue
- Side Effects
- Hot flashes (with testosterone suppression)
- Decreased libido and erectile dysfunction
- Initial testosterone flare (first 1–2 weeks)
- Bone density loss with long-term use
- +3 more
- Muscle soreness (satellite cell activation)
- Injection site irritation
- Hypoglycemia risk (modest, less than IGF-1 LR3)
- Stacks With
- —
- —